Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Characterization of 0839: A Tool Compound for Pre-Clinical Mode-of-Action Studies of Amylin Analogues Such as Cagrilintide
In people with T2D, a phase 1b study did not demonstrate improvement in HbA1c, however there was a placebo-adjusted WL of 8.5% after 12 weeks (Table 3)
Treatment with Dihexa at doses of 1.44-2.88 mg/kg administered intragastrically for three months significantly reduced escape latency and increased time spent in the target quadrant during probe trials
Patients should be prepared for this phase and understand that it indicates the treatment is working
US$ 29.61
US$ 23.05
US$ 24.44
US$ 26.71
US$ 20.70
US$ 21.76
US$ 23.85
US$ 25.38
US$ 24.00
